The Globe and Mail reports in its Wednesday, May 3, edition that Canaccord Genuity analyst Matt Bottomley is keeping his "buy" call on Curaleaf Holdings intact. The Globe's David Leeder writes in the Eye On Equities column that Mr. Bottomley gave his share target a $1.50 trim to $9. Analysts on average target the shares at $10.37. Mr. Bottomley says in a note, "Although the Q4 print was generally in line with our expectations and management's previously issued outlook on the top line, the quarter saw a moderate reduction in its adj. EBITDA margin profile on the back of pricing headwinds, unfavourable geographical mix and its conversion to U.S. GAAP." The Globe reported on Nov. 10, 2021, and on Dec. 23, 2021, that Mr. Bottomley continued to rate Curaleaf "buy." It was then worth $12.80 and $11.34. The Globe reported on May 11, 2022, and Aug. 10, 2022, that Mr. Bottomley continued to rate Curaleaf "buy." It was then worth $7.31 and $7.23. The Globe reported on Feb. 9, 2023, Stifel analyst Andrew Partheniou had reaffirmed his "buy" recommendation for Curaleaf, which could then be had for $4.93.